Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

Y. Loriot

h-index 18 View on Semantic Scholar

We have 4 of 62 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit.

This study represents the largest real-world cohort evaluating the referral-to-treatment trajectory in EPT, with patients referred to Gustave Roussy's Drug Development Department between January 1, 2007 and December 31, 2023.

Matthieu Roulleaux Dugage, C. Mazza, P. Matte et al. · 0 citations
Open access Sep 2026

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma

Background Cohort 1 of the phase III THOR trial met the primary endpoint of significantly longer overall survival (OS) with erdafitinib versus chemotherapy in patients with metastatic urothelial carcinoma (mUC) and select FGFR3/2 alterations who have progressed after prior anti–PD-(L)1 treatment. We present efficacy an...

Y. Loriot, N. Matsubara, S. H. Park et al. · 0 citations
Review Open access Sep 2026

PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [ 177 Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-f...

Hiba Noamen, Adam Bekkhoucha, A. Bernard-Tessier et al. · 0 citations
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.